Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…
Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline
Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…
Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30
Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…
Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value
Innovent’s Once-Weekly Oral GLP-1 IBI3042 Gets NMPA IND Clearance for Obesity
Innovent Biologics has received clearance from China’s National Medical Products Administration (NMPA) to begin clinical development of IBI3042, a potentially first-in-class once-weekly oral small-molecule GLP-1 receptor agonist, marking another…